DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
June 17, 2010
205 JEFFERSON STREET
JEFFERSON CITY, MO 65101

Committee Members Present
Joe Parks, MD (by phone)
Conrad Balcer, DO
Pat Bryant, PharmD
Gene Forrester, RPh
Steven Calloway, RPh

Committee Members Absent:
Henry Petry, DO, Chairman

Contractors in Attendance:
Rick Pope, PharmD, First Health Services
Jennifer Kemp-Cornelius, PharmD, ACS
Mark Roaseau, ACS
Tom Beetem, RPh, Infocrossing
Sophie Backes, ACS

MO HealthNet Staff Present:
George L. Oestreich, PharmD, Dep. Division Director
Rhonda Driver, RPh, Director of Pharmacy
Allison Lauf, RN
Mary Heet, RN
Jayne Zemmer, Social Services Manager
Angela Wilson, Unit Supervisor
Tisha McGowan, Unit Supervisor
Beth McQuaide, Special Assistant
DJ Johnson, Program Development Specialist
Lisa Clements, PhD, Clinical Director Psychology Program
Jenna Twehus, RN
Debbie Bradley, Medicaid Specialist
Terri Brondel, Correspondence and Information Spec.
Ian McCaslin, MO HealthNet Division Director

Others Attending:

Eric Blake, Merck	Patty Minear, Lilly	Jacquelyn Dungey, Lilly	Doug Erickson, Lilly	Jeff Himmelburg, GlaxoSmithKline
Grant Cale, BMS	Chad Stewart, BIPI	John Harris, Abbott	Paul Setlak, Abbott	Don Larsen, Forest
Robert Calder, Merck	Paul Konovodoff, Acorda	Todd Paulsen, Novo Nordisk	Carol Curtis, Astra Zeneca	Monica LaFran, Alcon
Scott Edelhauser, Alcon	Jeff Knappen, Allergan	Barbara Belcher, Merck	J Graham, J and J	Terry Rehmus, J and J
Rich Vardryn, Eisai	Susan Zalenski, J and J	Steve Strong, Astra Zeneca	Eric Gardner, Pfizer	Mike Kloos, Pfizer
Lee Ding, Genentech	Laurie Schmitt, Forest	Scot Green, Pfizer	Arnie Palmer, Taro	Gina Luebbering, Budget and Planning
Teri Kramer, Taro	Ashley Ricketts, UMKC	Aaron Hartman, UMKC	Eve Ehan, UMKC	Deidra Adams, Student
Todd Houldsworth,	Ray Carter, VCG Assoc.	Brad Raudabaugh, Astra Zeneca	William Dozier, Gilead	Jim McNamara, VIIV Healthcare
J Filmitdeer, Sanofi				

Many names on the sign-in sheet were illegible. Sign in sheet on file for review.

Welcome, Introductions and Opening Remarks	In the absence of Chairman Henry Petry, DO, George L. Oestreich, PharmD, MPA, Deputy Division Director called the meeting to order at 10:00 a.m.
Minutes Approval	Minutes of the March meeting were reviewed and approved as submitted.
Pharmacy Program/Budget Update	Dr. Oestreich presented a presentation entitled Pharmacy Program Update. Updated slides graphing the growth in eligibles, cost per work day, average prescription cost and pharmacy budget trend lines were shared. Dr. Oestreich expects to see a zero growth budget for next year. Fiscal Year 2010 MAC savings, Managed Care differentials and April 2010 facts (cost per participant, average Rx cost, number of Rx per participant and total number of Rx per month) were shared. Additional slides demonstrated information regarding Antipsychotic medication trends. Information focused on the most vulnerable pediatric population and included dosing above the recommended level and use of multiple agents. Dr. Oestreich shared troubling data as to how Missouri compares to 5 other states in these areas. The success of clinical management tools in the program was discussed and the impact of implementing a mental health drug clinical monitoring program was shared. Dr. Oestreich and Joe Parks, MD responded to questions from the Committee and the audience to clarify this data including.
DUR Report	Tisha McGowan, DUR Coordinator reported the DUR Board reviewed, at their April Meeting, and concurred with the recommendations made by the Drug Prior Authorization (PA) Committee at their March meeting. Ms. McGowan advised the Governor's Office had made four recent appointments to the DUR Board. These new members have all been confirmed by the Senate. Dr. John Newcomer was also reappointed to the Board.
Old Business	
Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule had been updated with all edits approved at the last quarter's meetings. This schedule may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf
New Business	
New Drug Review	**Discussion –** A listing of products recommended for open access, clinical edit, as a preferred drug list (PDL) product or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. • **Public Hearing –** A presentation scheduled for the product Sterlara was deferred by Johnson and Johnson. Brian Hutchinson, PharmD , Acorda, spoke in support of Ampyra. Lee Ding, Genentech addressed the group in support of preferred status for Acterna. • **Decision –** Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)
Clinical Edits **Psychotropic Edit Discssion**	• **Discussion** –Proposed clinical edit criteria documents for atypical antipsychotic medications, psychotropic medication polypharmacy, SSRIs and SNRI therapy were included in the meeting packet. Ms. Driver reviewed each document noting approval and denial criteria which included appropriate diagnosis and dosing not to exceed recommended daily dosing maximums. Ms. Driver noted that grandfathering of current therapy regimens would apply as well as room for physicians to cross taper patients to new therapies. The

	Division plans a staged implementation over several quarters for these edits beginning in October 2010. It was noted that some new products were missing from those listed in the documents and those will be added post new product review conclusion. Discussion ensued regarding the concurrent use of SSRI and SNRIs for more than 30 days denial criteria. A 90 day cross taper period was discussed. The Committee requested feedback from DUR Board on this issue. The adult maximum dose for Geodon listed on table 1 of the atypical Antipsychotic criteria document was incorrect and will be corrected. ● Public Hearing – A presentation scheduled by Pfizer on the product Geodon was waived by the planned presenter. ● Decision –The Committee voted to accept these edits as presented. However recommends the Division revisit antipsychotic dosing limits for children post implementation. (See Roll Call Votes)
Preferred Drug List (PDL) Annual Review: **Beta Adrenergic Blockers and Diuretic Combinations**	Products under review this quarter are currently on the PDL with contracts expiring in September 2010. Recommended changes to the current edits were bolded on the criteria documents presented (See Meeting Packet), for easy identification. • **Discussion –**Ms. Driver reviewed the criteria document. No change to the current edit was recommended. • **Public Hearing-**Laurie Schmidt, Forest Pharmaceuticals provided information on Bystolic, requesting preferred status for the product. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
Calcium Channel Blocker/Dihydropyridines	• **Discussion –** Ms. Driver reviewed the criteria document. No change to the current edit was recommended. • **Public Hearing-** No comments were entered. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
Calcium Channel Blocker/Non Dihydropyridines	• **Discussion –** Ms. Driver reviewed the criteria document. No change to the current edit was recommended. • **Public Hearing-** No comments were entered. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
Angiotensin II Receptor Calcium Channel Blocker Combinations	• **Discussion –** The group reviewed the proposed criteria document. Ms. Driver noted the addition of a new product to non-preferred status, Twynsta. • **Public Hearing-** Derek Terada, PharmD,MBA with Boehringer Ingelheim.presented data and information on the product Twynsta. The Committee was asked to consider preferred status for the product. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
Cox II Inhibitors	• **Discussion –** Ms. Driver reviewed the criteria document pointing out there were no changes being recommended to the current PDL edit. Clinical criteria will remain in place.

	• **Public Hearing-**No comments were entered. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
Hepatitis C Agents	• **Discussion –** The group reviewed the criteria document. There were no changes recommended to the current PDL criteria. All products in this class remain preferred. • **Public Hearing-** No comments were entered. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
Amylin Analogs	• **Discussion –** Ms. Driver reviewed the criteria document noting no change. All products in this category were recommended as preferred. Up front clinical criteria will remain in place. • **Public Hearing-**No comments were entered. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
GLP-1 Receptor Agonists	• **Discussion –** Ms. Driver pointed out the addition of a new product (Victoza) to this class under non preferred status. Up front clinical criteria remain in place. • **Public Hearing-**Todd Paulsen, PharmD with Novo Nordisk shared information and provided a handout to the members for their information on Victoza.. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
DPP-IV Inhibitors	• **Discussion –**The addition of a new product, Onglyza, to non preferred stauts was noted as Ms. Driver summarized the criteria document. • **Public Hearing-**Bryan Goeckner, PharmD, Bristol Meyers Squibb summarized a handout on Onglyza and requested preferred status consideration. Dr. Robert Collier addressed the group in support of the preferred product, Januvia. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
Onychomycosis Antifungals	• **Discussion –** Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria other than the addition of a new product, Terbinex to non preferred status. Diagnosis, dosing and duration of therapy parameters will remain in place. • **Public Hearing-**No comments were entered. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
Proton Pump Inhibitors	• **Discussion –** The group reviewed the criteria document noting changes to the non preferred products with the addition of Previcid OTC and Lansoprazole Rx. The step therapy and approval diagnosis requirements within this edit remain unchanged. • **Public Hearing-** No comments were entered • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block

	vote. This recommendation was add to the group vote. (See Roll Call Vote)
Ribavirins	• **Discussion –**No change to the existing edit was recommended. • **Public Hearing-** No comments were entered. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote))
Topical Immunomodulators	• **Discussion –** No changes were recommended to the current PDL criteria. All products in the class remain preferred. • **Public Hearing-**No comment was entered. • **Decision –** The In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
Topical Androgenic Agents	• **Discussion –** No changes were recommended to the current PDL criteria. • **Public Hearing-**No comments were entered. • **Decision –** In the interest of time the Committee agreed to group all PDL recommendations into one block vote. This recommendation was add to the group vote. (See Roll Call Vote)
Preferred Drug List Discussion/Therapeutic Classes	A handout of therapeutic categories to be considered for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This meeting will be an annual review of products with contracts expiring December 31, 2009. This handout was also provided to all attendees and will be posted to the Division's web page http//:www.dss.mo.gov.mhd. Ms. Driver informed the attendees that the Division is working with Magellan (First Health Services) to again extend the contracts for some the classes up for review in order to stagger the annual review period so that the number of classes under review at the September meeting is more manageable.
Program Utilization: Top 25 Drugs by Cost	Top 25 drug list for dates of service between second quarter 2009 through March 2010 was provided for the Committees' information. This report was provided in two formats; ranked by number of claims and ranked by amount paid. Copies were available to all attendees.
Clinical Edit Summary Report	An overview report of the clinical edit and prior authorization request transaction counts for the month of June 2010 was provide for all attending. The report provided total transaction counts as well has information on the outcome (approval or denial) of the request.
Call Center Statistics	A handout detailing pharmacy help desk call center activity was provided for all attending. Statistics for June 2010 were included.
Adjourn	The next meeting is scheduled for September 16, 2010. The Drug PA committee went into Executive Session for the sole purpose of discussing individual recipient specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See attached roll call)

Roll Call Votes – June 17, 2010

Member	***New Drug Review***	***Clinical Edits***	***PDL***	***Closed Session***	***Adjourn***
Henry Petry, D.O.	Absent	Absent	Absent	Absent	Absent
Gene Forrester, R. Ph.	**Second**	Yeah	Yeah	Yeah	**Second**
Steven Calloway, R. Ph.	Yeah	*Yeah*	Yeah	*Second*	Yeah
Pat Bryant, Pharm.D.	Yeah	**Second**	**Second**	Yeah	**Motion**
Conrad Balcer, D.O.	**Motion**	***Motion***	***Motion***	**Motion**	Yeah
Joe Parks, M.D.	Yeah	*Yeah*	Absent	*Absent*	Absent

EXECUTIVE SESSION

June 17, 2010

Committee Members Present
Joe Parks, MD (by phone)
Conrad Balcer, DO
Pat Bryant, PharmD
Gene Forrester, RPh
Steven Calloway, RPh

Committee Members Absent:
Henry Petry, DO, Chairman

Contractors in Attendance:
Rick Pope, PharmD, First Health Services
Jennifer Kemp-Cornelius, PharmD, ACS
Mark Roaseau, ACS
Tom Beetem, RPh, Infocrossing
Sophie Backes, ACS

MO HealthNet Staff Present:
George L. Oestreich, PharmD, Dep. Division Director
Rhonda Driver, RPh, Director of Pharmacy
Allison Lauf, RN
Mary Heet, RN
Jayne Zemmer, Social Services Manager
Angela Wilson, Unit Supervisor
Tisha McGowan, Unit Supervisor
Beth McQuaide, Special Assistant
DJ Johnson, Program Development Specialist
Lisa Clements, PhD, Clinical Director Psychology Program
Jenna Twehus, RN
Debbie Bradley, Medicaid Specialist
Terri Brondel, Correspondence and Information Spec.

	EXECUTIVE SESSION
Minutes Review	Minutes of the March 2010 Executive Session were approved as submitted
Case Reviews	No cases were presented for review.
Adjourn	Executive session adjourned. (See roll call vote)